# Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis

> **NCT01932554** · PHASE2 · WITHDRAWN · sponsor: **St. Louis University**

## Conditions studied

- Sickle Cell Disease
- Hb-SS Disease With Vasoocclusive Pain
- Hemoglobin SS Disease With Vasoocclusive Crisis
- Other Sickle Cell Disease With Vaso-Occlusive Pain
- Hemoglobin SS Disease With Crisis

## Interventions

- **DRUG:** Abciximab
- **DRUG:** Placebo
- **OTHER:** Intravenous hydration
- **DRUG:** Ibuprofen
- **DRUG:** Parenteral narcotic
- **OTHER:** Incentive spirometry
- **OTHER:** Supplemental oxygen

## Key facts

- **NCT ID:** NCT01932554
- **Lead sponsor:** St. Louis University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2013-11
- **Primary completion:** 2015-03
- **Final completion:** 2015-03
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Insufficient recruitment
- **Last updated:** 2015-03-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01932554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01932554, "Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis". Retrieved via AI Analytics 2026-07-01 from https://api.ai-analytics.org/clinical/NCT01932554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*